



Short term effects of chloroquine on the Testis of Sprague Dawley rats

Akinribido F.A, Noronha C.C, Okanlawon O.A (2011)

Dept Department of Biological Sciences, Bells University of Technology Ota, Ogun State

Dept Of Anatomy, College of Medicine, University of Lagos, Idi-Araba, Lagos State

(Research Work)

Correspondence to: Akinribido F.A, fumibos@yahoo.co.uk; +2348023654975

ABSTRACT

Ten male rats were exposed to chloroquine phosphate injection intraperitoneally (IP) for three days. The treated rats received 0.125ml/100g body weight of chloroquine phosphate injection intraperitoneally. Control rats received the same amount of normal saline intraperitoneally.

Histologically, there was a little constriction of the seminiferous tubules with few intestinal cells (of leydig) in the treated rats compared with controls.

Stereologically, there was a reduction in the estimated absolute volume of the seminiferous tubules in the treated rats compared with controls.

Keywords: Testis, Sprague dawley rats, chloroquine, histology, stereology

INTRODUCTION

Approximately 50-70% of chloroquine in plasma is bound to plasma proteins. The tissues exhibit particularly high binding to chloroquine especially those containing melanin, for example the retina. Significant binding also occurs in the liver, kidney and spleen. Chloroquine (Resochin, Avloclor, Nivaquine, Arelen) $C_{18}H_{26}ClN_3$ 7-Chloro-4-(4'-diethylamino-1'-methylamino)quinoline. Chloroquine is a white powder with a bitter taste, prepared by chemical synthesis. It is available as sulphate and phosphate salts. The sulphate (1 in 3) and the phosphate (1 in 4) are soluble in water. Chloroquine is best known as an antimalarial agent but it is also used in the treatment of rheumatoid arthritis. Chloroquine is effective against the erythrocytic stages of all four plasmodium species which cause human malaria with the exception of matured plasmodium falciparum gametocytes. The exact mechanisms of the action of chloroquine against malaria parasites are not fully understood. Parasitized red cells accumulate approximately 100-600 times as much chloroquine. The concentration of chloroquine in malaria parasite requires energy and is thought to require a membrane. There are three theories on the way state as that chloroquine, being a basic compound, is protonated in the lysosomes thus raising lysosomal pH. This effect may raise the intralysosomal pH above a critical level all bring about loss lysosomal function. This would reduce the parasite's digestion of haemoglobin, and thus prevent its growth.

Chloroquine intercalates into double stranded DNA and inhibits both DNA and RNA synthesis. The intercalation theory suggests that chloroquine may be bound with increased affinity by certain parts of the genome and be toxic to the malaria parasite by selective accumulation in specific genes, inhibiting their expression. The ferriprotophyrin IX (FP) which inhibits sequestration of FP into malaria pigment. This could impair haemoglobin degradation and permits damage to the food vacuole sufficient to discharge its Ph gradient. Antimalaria activity is possessed equally by the enantiomers of chloroquine and the main metabolite desethylchloroquine is also active against chloroquine-sensitive Plasmodium. Chloroquine also has anti-inflammatory activity. The concentrations of chloroquine or hydrochloroquine found in serum in the treatment of rheumatoid disease raise the pH of acid vesicles in mammalian cell within 3-5 min in vitro. This and the observation that the view that chloroquine and hydroxychloroquine act in the rheumatic disease by raising the pH of acid vesicles. Effects of raised vesicle pH include inhibition lysosomal proteolysis, interference with the targeting of acid proteases and inhibition of cellular maturation. Raise pH in the macrophage vesicle can interfere with antigen processing. This is thought to be the explanation for the

impaired antibody response to pre-exposure to human diploid cell rabies vaccine found in individual receiving concurrent chemoprophylaxis with chloroquine. In addition, chloroquine inhibits the chemotactic response of mononuclear cells and suppresses lymphocytes transformation.

MATERIALS AND METHODS

The twenty female Sprague- Dawley rats were collected from the Animal House of the College of Medicine University of Lagos Akoka, Lagos State.

They weighed between 100-150g and were fed with the normal rat feed from Pfizer PLC Ikeja Lagos. Weight of animals was taken twice daily throughout the duration of the experiment. Ten female rats were used as controls. The remaining ten female rats were labelled by ear puncture as treated rats and kept in cages. Administration of drug was 0.125ml of chloroquine /100g body weight for 3 days intraperitoneally. Chloroquine phosphate injection was obtained from the community pharmacy of the Lagos university teaching hospital (40mg/ml chloroquine phosphate injection). The control received the same quantity of normal saline.

Animal Sacrifice

At the expiration of the treatment the animals were sacrificed by diethyl ether decapitation and the rats testis was removed for morphological and histological assessment.

Histological Analysis

The twenty male rats were sacrificed as discussed earlier after treatment with the chloroquine phosphate injection. The rats testis was removed and fixed in Bouin's fluid. The specimen of equal length was cut transversely and longitudinally into serial cross sections of 3µm normal thickness with Reichert Jung Supercut Microtome for control and treated rats. The tissue was sectioned using tissues preparation tissues method with hematoxylin and eosin stains and examined the light binocular microscope at a magnification of 100 and 400 respectively.

Stereological Analysis

The vertical sections of the histochemical preparation of stratum length of 0.5cm from 10 control and 10 treated rats testis was made at a final print magnification of 100 and 400 respectively.

5 slides will be obtained from the control and 5 slides from the treated rats.

For each of the fractions, the N_T/A □ number of test points counted in the rats testis, per unit area of the fractions were estimated by point counting method using the forbidden rule Hans Gundersen, 1977) which states that any structure that touches the forbidden line must not be counted. The reference volume $V(\text{ref})$ of rats seminiferous tubules was estimated by point counting (Wiebel, 1979, Gundersen et al, 1988).

At Magnification (M) = 100 final magnification using a Square Grid of test point diameter (d) = 1.2cm apart. The test system used in the light microscopic analysis within a square frame measuring 20cm x 20cm onto which microscopic image was projected using a wild leitz microscope equipped with a mirror at a magnification of 25 on a white screen.

Estimated $V(\text{ref}) = (\text{stratum length}) \times \frac{d^2}{M^2} \times \text{mean } N_T/A (\text{structure})$.

$$M^2$$

d= diameter of test grid

M=magnification of projection

The relevant volume density of rats seminiferous tubules of the fractions V_v (structure) were estimated on the same section at a final magnification of 100. Each field was projected onto a test system consisting of three sets of points with numerical densities in the ratio 1:4:16. The corresponding distance between the test points of each set were 4.8, 2.4 and 1.2cm respectively.

The criteria for test point design and allocation were based on efficiency considerations; thus approximately the same number of test points (which does not need to exceed 200) should be in each structure within each organ (Gundersen and Jensen, 1987; Gundersen et al., 1988; Cruz Orive and Wiebel; 1990). The required volume density of the fractions were estimated as follows:

$$\text{Estimated } V_v(\text{structure}) = N_{vR} \times N_T/A(\text{ structure})$$

$$V_v = \text{volume density } N_{vR} = \text{numerical density ratio}$$

Finally, the absolute volume of rats seminiferous tubules was estimated using this equation.

$$V(\text{structure}) = V_v(\text{structure}) \times V(\text{ref})$$

$$V(\text{structure}) = \text{Absolute volumes of structure}$$

$$V_v(\text{ref}) = \text{Reference volume of structure}$$

Statistics

Statistical analysis was carried out using t- Distribution (t- test).

RESULTS

TABLE1: MEAN NUMBER OF TEST POINTS PER UNIT AREA (N_T/A) OF SEMINIFEROUS TUBULES

GROUP n=20	Mean (N_T/A)
CONTROL (CO)	30.88
CHLOROQUINE TREATED (CQ)	25.13

CO=CONTROL RATS

CQ= CHLOROQUINE TREATED RATS

TABLE2: MEAN ESTIMATED ABSOLUTE VOLUMES (CM^3) OF SEMINIFEROUS TUBULES

TISSUE	CONTROL RATS n=10	CHLOROQUINE TREATED RATS n=10
TESTIS(SEMINIFEROUS TUBULES)	$6.86 \times 10^{-2} \pm 0.86^a$	$1.14 \times 10^{-2} \pm 1.39^b$

a=Mean±S.E.M

b=p<0.05

DISCUSSION

Histologically, chloroquine has deleterious effects on the structures of the testis especially the seminiferous tubules of the treated rats.

Stereologically, there was a reduction in the treated rats compared with controls.

CONCLUSION

Chloroquine should be taken under prescription by licensed medical professional.

REFERENCES

1. Akoachere M, Buchholz K, Fischer E, Burhenne J, Haefeli WE, Schirmer RH, Becker K. In vitro assessment of methylene blue on chloroquine-sensitive and -resistant *Plasmodium falciparum* strains reveals synergistic action with artemisinins. *Antimicrob Agents Chemother*. 2005 Nov;49(11):4592-7.
2. Akompong T, VanWye J, Ghorri N, Haldar K. Artemisinin and its derivatives are transported by a vacuolar-network of *Plasmodium falciparum* and their anti-malarial activities are additive with toxic sphingolipid analogues that block the network. *Mol Biochem Parasitol*. 1999 Jun 25;101(1-2):71-9.
3. Balint GA. Artemisinin and its derivatives: an important new class of antimalarial agents. *Acta Trop*. 2005 Jun;94(3):181-90.
4. Birku Y, Makonnen E, Bjorkman A. Comparison of rectal artemisinin with intravenous quinine in the treatment of severe malaria in Ethiopia. *East Afr Med J*. 1999 Mar;76(3):154-9.
5. Chaijaroenkul W, Pruktal P, Muhamad P, Na-Bangchang K. Assessment of in vitro antimalarial interactions between dihydroartemisinin and fosmidomycin. *Southeast Asian J Trop Med Public Health*. 2007 Sep;38(5):791-5.
6. Chim P, Lim P, Sem R, Nhem S, Maciejewski L, Fandeur T. The in-vitro antimalarial activity of ferrochloroquine, measured against Cambodian isolates of *Plasmodium falciparum*. *Ann Trop Med Parasitol*. 2004 Jun;98(4):419-24.
7. Cumming JN, Wang D, Park SB, Shapiro TA, Posner GH. Design, synthesis, derivatization, and structure-activity relationships of simplified, tricyclic, 1,2,4-trioxane alcohol analogues of the antimalarial artemisinin. *J Med Chem*. 1998 Mar 12;41(6):952-64.
8. Duraisingh MT, Cowman AF. Contribution of the *pfmdr1* gene to antimalarial drug-resistance. *Curr Drug Targets Infect Disord*. 2004 Mar;4(1):1-10.
9. Farooq U, Mahajan RC. Drug resistance in malaria. *J Vector Borne Dis*. 2004 Sep-Dec;41(3-4):45-53.
10. Gbotosho GO, Happi CT, Ganiyu A, Ogundahunsi OA, Sowunmi A, Oduola AM. Potential contribution of prescription practices to the emergence and spread of chloroquine resistance in south-west Nigeria: caution in the use of artemisinin combination therapy. *Malar J*. 2009 Dec 30;8:313.
11. Hayton K, Su XZ. Genetic and biochemical aspects of drug resistance in malaria parasites.
12. Hoppe HC, van Schalkwyk DA, Wiehart UI, Meredith SA, Egan J, Weber BW. Antimalarial quinolines and artemisinin inhibit endocytosis in *Plasmodium falciparum*. *Antimicrob Agents Chemother*. 2004 Jul;48(7):2370-8.
13. Hunt P, Afonso A, Creasey A, Culleton R, Sidhu AB, Logan J, Valderramos SG, McNae I, Cheesman S, do Rosario V, Carter R, Fidock DA, Cravo P. Gene encoding a deubiquitinating enzyme is mutated in artesunate- and chloroquine-resistant rodent malaria parasites. *Mol Microbiol*. 2007 Jul;65(1):27-40.
14. Hutagalung R, Paiphun L, Ashley EA, McGready R, Brockman A, Thwai KL, Singhasivanon P, Jelinek T, White NJ, Nosten FH. A randomized trial of artemether-lumefantrine versus mefloquine-artesunate for the treatment of uncomplicated multi-drug resistant *Plasmodium falciparum* on the western border of Thailand. *Malar J*. 2005 Sep 22;4:46.

15. Krishna S, Woodrow CJ, Staines HM, Haynes RK, Mercereau-Puijalon O. Re-evaluation of how artemisinin works in light of emerging evidence of in vitro resistance. *Trends Mol Med*. 2006 May;12(5):200-5. Epub 2006 Apr 17.
16. Kyavar L, Rojanawatsirivet C, Kollaritsch H, Wernsdorfer G, Sirichaisinthop J, Wernsdorfer WH. In vitro interaction between artemisinin and chloroquine as well as desbutyl-benflumetol in *Plasmodium vivax*. *Wien Klin Wochenschr*. 2006;118(19-20 Suppl 3):62-9.
17. Mayxay M, Barends M, Brockman A, Jaidee A, Nair S, Sudimack D, Pongvongsa T, Phompida S, Phetsouvanh R, Anderson T, White NJ, Newton PN. In vitro antimalarial drug susceptibility and pfprt mutation among fresh *Plasmodium falciparum* isolates from the Lao PDR (Laos). *Am J Trop Med Hyg*. 2007 Feb;76(2):245-50.
18. O'Neill PM. The therapeutic potential of semi-synthetic artemisinin and synthetic endoperoxide antimalarial agents. *Expert Opin Investig Drugs*. 2005 Sep;14(9):1117-28.
19. Taylor SM, Juliano JJ, Meshnick SR. Artemisinin resistance in *Plasmodium falciparum* malaria. *N Engl J Med*. 2009 Oct 29;361(18):1807;
1. Touré AO, Koné LP, Jambou R, Konan TD, Demba S, Beugre GE, Koné M. [In vitro susceptibility of *P. falciparum* isolates from Abidjan (Côte d'Ivoire) to quinine, artesunate and chloroquine]. *Sante*. 2008 Jan-Mar;18(1):43-7.